Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors kidneyintelX.dkd


Our leadership has over 200 years of collective diagnostics industry experience.

We have created a dynamic environment and culture where our team members, our executive leadership team, the Board of Directors and the Advisory Board seek to challenge and align company strategies to deliver maximum value for all stakeholders.

James McCullough

James McCullough has served as our co-founder and Chief Executive Officer since our inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.

Fergus Fleming

Fergus Fleming has served as our Chief Technology Officer since our inception. Mr. Fleming has served as managing director of FF Consulting Limited, providing Product Development and Commercialization support to Medical Devices and Diagnostics companies since June 2013. Roles in this period include Head of Business Development for Oncomark Limited from November 2016 to October 2018 and from 2013, he served in various roles at EKF Diagnostics plc. He has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.

Howard Doran

Howard Doran served as our Chief Business Officer from September 2023 – April 2024. He has now assumed the role of President, with responsibility for global sales and marketing. Prior to joining Renalytix, he was President and Chief Executive Officer at LipoScience, where he stayed until its successful acquisition by LabCorp. Mr. Doran also served as President and Chief Operating Officer at Constitution Medical, Inc. and President of Hologic’s global diagnostics business. Earlier in his career, he was on the management team of Cytyc Corporation, holding a number of senior commercial roles, including physician sales and marketing, managed care, and laboratory sales and marketing. Mr. Doran received his B.S. degree in Management from West Chester University of Pennsylvania.

Joel R. Jung
MBA, Interim CFO

Joel R. Jung joined Renalytix as interim Chief Financial Officer in May 2024. From 2008 – 2020, he also served as CFO for various life sciences, biotech, and diagnostic companies, including Celera Corporation, Agraquest, Inc., BioNano Genomics, and Counsyl, Inc. Most recently, he was Chief Financial Officer at Minerva Surgical, a commercial-stage medical device company. He received his BS in Aeronautical and Astronautical Engineering from Purdue University and his MBA in Finance from the Haas School of Business at the University of California, Berkeley.

Michael J. Donovan

Michael J. Donovan, Ph.D., M.D. has served as our Chief Medical Officer since our inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.

Christopher Mills2023-01-10T08:25:01+00:00

Christopher Mills has served as a member of our board of directors since our inception. Mr. Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management, which he co-founded in 1993. He is chief executive officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and chairman and chief executive officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.

Erik Lium

Erik Lium, Ph.D. has served as a member of our board of directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Dr. Lium also serves as chairman of the board of managers of Kantaro. Prior to joining Mount Sinai, Dr. Lium served as the assistant vice chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), the UCSF principal investigator for the Bay Area National Science Foundation I-Corps node, and assistant vice chancellor of Research. Dr. Lium served as president of LabVelocity Inc. prior to its acquisition in 2004. He pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University.

Daniel J. Levangie2023-01-10T08:27:37+00:00

Daniel J. Levangie was appointed to the Company’s board of directors in August 2021. He is an experienced executive and long-serving board director in the diagnostics and medical devices industry. Mr. Levangie is co-founder and manager of ATON Partners, a private investment firm, and president and CEO of CereVasc, LLC, a medical device company. He has also served on the board of directors of Exact Sciences Corporation since 2010. From 2013 through January 2017, Mr. Levangie served as president of Insulet Drug Delivery Systems and served as a lead director of Insulet Corporation. From 2011 through 2013, Mr. Levangie was chief executive officer of Dune Medical Devices, Inc., and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013. Previously, he held executive management positions with Cytyc Corporation including executive vice president and chief operating officer, chief executive officer and president until the acquisition of Cytyc by Hologic, in 2007. He served on the board of Hologic from 2007 to 2009. Mr. Levangie holds a B.S. in Pharmacy from Northeastern University.

Catherine Coste2023-07-12T12:06:29+00:00

Catherine Coste was appointed to the Company’s Board of Directors in June 2023. Ms. Coste retired from Deloitte and Touche LLP (“Deloitte”) in 2020, where she was a Senior Partner, and served as one of Deloitte’s Life Sciences industry executive leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit, and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. She also serves as a Director at both Minerva Surgical, Inc., where she is Chair of the Audit Committee and a Member of the Compensation Committee, and Biomerica, Inc., where she is Chair of the Audit Committee, and serves on both the Compensation Committee and the Nominating and Corporate Governance Committee. Ms. Coste’s experience includes, but is not limited to, Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. She is a Certified Public Accountant, who earned her B.A. in business administration, accounting, from California State University, Hayward.

Salim Hamir

Salim Hamir is a Chartered Accountant with leadership experience in several companies. Salim has been with EKF Diagnostics Holdings Plc over the last 10 years serving in various capacities, currently as Company Secretary and Head of Corporate Affairs dealing in all matters in respect to M&A, investor relations and governance. Salim has played instrumental roles in the public listings of RenalytixAI, Verici Dx and Trellus Health and serves as Company Secretary for all these companies. Salim also serves as Chief Financial Officer for Trellus Health. Salim has extensive experience providing strategic advice on mergers and acquisitions, fundraising and AIM listings, cost reduction, tax planning, and implementation of new systems and processes. Prior to these roles, Mr. Hamir served as the Finance Director for Quotient Diagnostics and the Wilton Group.

Nominated Advisor2023-01-10T08:33:07+00:00

Stifel Nicolaus Europe Limited
150 Cheapside

Joint Broker2023-01-10T08:34:06+00:00

Stifel Nicolaus Europe Limited
150 Cheapside

2 Gresham Street

Legal Advisors to the Company2023-01-10T08:34:44+00:00

Cooley (UK) LLP
69 Old Broad Street

Auditors and Reporting Accountants2023-01-10T08:35:47+00:00

PKF Littlejohn LLP
1 Westferry Circus
Canary Wharf
E14 4HD


Ernst & Young LLP
99 Wood Avenue S.
Iselin, NJ 08830

Media and Investor Relations2024-03-20T18:08:03+00:00

Walbrook PR Limited
4 Lombard Street
Tel: +44 (0)20 7933 8780

CapComm Partners
Peter DeNardo
Tel: +1 415-389-6400


Link Group
Central Square
29 Wellington Street

Tel: 0371 664 0300

Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.

Go to Top